SML2486
Peramivir trihydrate
≥98% (HPLC)
Synonym(s):
(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxycyclopentanecarboxylic acid trihydrate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H28N4O4 · 3H2O
CAS Number:
Molecular Weight:
382.45
UNSPSC Code:
51111800
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -125 to -145°, c = 0.1 in H2O
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
N([C@H]1[C@@H]([C@@H]([C@H](C1)C(=O)O)O)[C@@H](NC(=O)C)C(CC)CC)C(=N)N.O.O.O
InChI
1S/C15H28N4O4.3H2O/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23;;;/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19);3*1H2/t9-,10+,11+,12-,13+;;;/m0.../s1
InChI key
RFUCJKFZFXNIGB-ZBBHRWOZSA-N
Biochem/physiol Actions
Influenza viral neuraminidase inhibitor
Peramivir exhibits antiviral activity against type A and B influenza virus including pandemic influenza A/H1N1 virus. It also exhibits its antiviral effects on avian influenza viruses like H5N1 and H9N2 strains.
Peramivir is an Influenza viral neuraminidase inhibitor.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Zhengtu Li et al.
BMC infectious diseases, 16, 325-325 (2016-07-10)
China-made Peramivir, an anti-influenza neuraminidase inhibitor drug, is manufactured and widely used in China. Although effective if initiated within 48 h of the onset of symptoms, yet we observed that this drug shows an inconclusive efficacy if treatment is delayed in
Masanori Kobayashi et al.
Antiviral research, 139, 41-48 (2016-12-26)
High morbidity and mortality associated with human cases of highly pathogenic avian influenza (HPAI) viruses, including H5N1 influenza virus, have been reported. The purpose of the present study was to evaluate the antiviral effects of peramivir against HPAI viruses. In
Jung-Wan Yoo et al.
Journal of medical virology, 87(10), 1649-1655 (2015-05-07)
The clinical efficacy of peramivir in the treatment of severe seasonal influenza in critically ill patients admitted to an intensive care unit (ICU) is not well established. The aim of this study was to compare the clinical efficacy of peramivir